Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
'We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.'
After closing, VB Spine will become a strategic partner to Stryker with exclusive access to Mako Spine and Copilot for use with VB Spine's implants in spine procedures. The transaction will enhance the focus of both Stryker and VB Spine to meet the needs of customers and their patients and is expected to achieve faster growth and deliver greater value for all stakeholders.
'We have long admired Stryker for its comprehensive spine portfolio, incredible talent, and strong culture,' said Marc, John and Anthony Viscogliosi, Co-Founders of Viscogliosi Brothers, LLC. 'We see a tremendous opportunity to provide the focus, surgeon-centric innovation, and commercial execution needed to grow the business and further impact patient lives and outcomes.'
The definitive agreement also includes a binding offer to acquire Stryker's spinal implants business in France, subject to required consultations with employees and/or employee representatives. The sale of Stryker's spinal implants business in other international markets is anticipated, pending satisfaction of legal and regulatory requirements, including any required consultations. The transaction is expected to close in the U.S. in the first half of 2025, subject to customary closing conditions. Stryker's U.S. spinal implants business and VB Spine will continue to operate as separate entities and proceed with business as usual until the transaction closes.
In connection with the transaction, Barings, LLC is an investor and financial partner to Viscogliosi Brothers.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
About Viscogliosi Brothers
Viscogliosi Brothers is a family-owned New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 42 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of multiple businesses in the spine industry specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedics Technologies, among others. For more information, visit https://www.vbllc.com/.
About Barings
Barings is a $421+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions.*Assets under management as of December 31, 2024
Contacts
For investor inquiries please contact:Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 orjason.beach@stryker.com
John Nguyen, Senior Director, Investor Relations at 269-385-2600 or john.nguyen1@stryker.com
For media inquiries please contact:Jenny Braga, Director, Communications and Public Relations at 269-385-2600 or jenny.braga@stryker.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
29 minutes ago
- Business Insider
‘This Is a No-Go Zone,' Says Top Investor About Figma Stock
Figma (NYSE:FIG) stock made a splash when it went public late last month, with shares tripling on their first day of trading. But the early euphoria has faded – the stock now trades about 31% below its day-one close. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even so, the IPO was a significant milestone for the design platform, which counts roughly 13 million active users and has delivered steady revenue growth over the past two years, including a 41% jump in Q2 2025. Yet, impressive growth alone isn't enough to sway everyone. Top investor Michael Wiggins De Oliveira, who is among the top 3% of TipRanks' stock pros, warns that jumping on the bandwagon now could be a costly mistake. 'I don't see a clear enough inflection for Figma to maintain its pricing power or growth profile over the next few quarters to justify its current multiple,' Wiggins De Oliveira explains. While the investor acknowledges the 'impressive userbase' and rapid revenue growth, he points to concerns that weaken the risk-reward profile. Chief among them is the growing narrative that AI could erode Figma's competitive moat. With technological disruption moving at breakneck speed, Wiggins De Oliveira questions whether the company can sustain its pace of year-over-year growth. Competitors could introduce advances that replicate core features of Figma's platform, undermining its uniqueness. 'The company is up against a challenging narrative that AI could disrupt much of its underlying offering,' the investor adds, projecting that revenue growth could slow to 30%–35% annually. Beyond growth concerns, Wiggins De Oliveira also casts doubt on the quality of Figma's cash flow profile. While the company posted a notable swing to nearly $100 million in free cash flow in Q1 2025, the investor cautions that the figure may have been flattered by one-off factors tied to its IPO filing. Stripping those out, he estimates sustainable annual free cash flow closer to $250 million at best – a figure that, when set against its market cap, leaves FIG trading at an expensive ~160x forward free cash flow. 'Outperformance comes from patience and picking your spots – and for me, FIG just doesn't make the cut,' concludes Wiggins De Oliveira, who rates FIG a Sell. (To watch Michael Wiggins De Oliveira's track record, click here) For now, FIG is too new to have analyst ratings, but with its IPO, early volatility, and high-profile debate, Wall Street attention is likely to grow in the months ahead. (See FIG stock analysis) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Los Angeles Times
an hour ago
- Los Angeles Times
UnitedHealth Group shares climb as Buffett's Berkshire Hathaway discloses stake in the insurer
Shares of UnitedHealth Group are surging before the market open Friday as Warren Buffett's Berkshire Hathaway disclosed that it recently purchased shares of the beleaguered insurer. Berkshire Hathaway bought around 5 million shares of UnitedHealth last quarter, according to a regulatory filing. The stake was valued at about $1.57 billion. Buffett plans to retire as CEO at the end of the year after six decades of building Berkshire Hathaway. Many investors comb through Berkshire's filings every quarter because they like to follow Buffett's moves. The filing doesn't make clear who at Berkshire handled the investment. Besides Buffett, Ted Weschler and Todd Combs also pick stocks, but they generally handle smaller portfolios and Combs also serves as Geico's CEO. Besides stocks, Berkshire owns dozens of companies in a variety of industries including Geico insurance, BNSF railroad, several major utilities and an assortment of manufacturing and retail companies. The Omaha, Nebraska-based company's holdings include many well-known brands like See's Candy and Dairy Queen. UnitedHealth has been dealing with a series of difficulties. Last month the company said that it was cooperating with federal criminal and civil investigations involving its market-leading Medicare business. The health care giant said at the time that it had contacted the Department of Justice after reviewing media reports about investigations into certain elements of its business. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper has since said that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth's stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged some more after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned, and the company withdrew its forecast entirely, saying that medical costs from new Medicare Advantage members were higher than expected. UnitedHealth's stock jumped more than 12% in premarket trading on Friday. Still, the stock has lost roughly half its value in the past year. Chapman writes for the Associated Press.
Business Insider
an hour ago
- Business Insider
J.P. Morgan Sticks to Its Buy Rating for Nisource (NI)
In a report released on August 13, Richard Sunderland from J.P. Morgan maintained a Buy rating on Nisource, with a price target of $46.00. The company's shares closed yesterday at $41.95. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Sunderland is a 3-star analyst with an average return of 2.7% and a 54.97% success rate. Sunderland covers the Utilities sector, focusing on stocks such as Atmos Energy, Spire, and Edison International. In addition to J.P. Morgan, Nisource also received a Buy from BMO Capital's James Thalacker in a report issued on August 6. However, on August 14, TR | OpenAI – 4o downgraded Nisource (NYSE: NI) to a Hold. The company has a one-year high of $43.51 and a one-year low of $31.90. Currently, Nisource has an average volume of 4.23M. Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NI in relation to earlier this year. Most recently, in June 2025, Melanie B. Berman, the EVP Administration & CHRO of NI sold 6,227.00 shares for a total of $245,468.34.
